phrykt

Abvc Biopharma, Inc. (ABVC): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ABVC were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No ABVC insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ABVC short interest

Low short interest. 2.3% of ABVC shares are sold short: about 1 share in 44. Over the last 12 reports the number of shares short went up 121%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 602,938 ABVC shares were sold short, 2.3% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 30,302 shares, buying them all back would take about 19.9 trading days (days to cover).

Shares short, % of all shares

2.26%May 15Oct 302.45%

Days to cover

19.9May 15Oct 3022.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026602,9382.26%+2%30,30219.9
Oct 15, 2026589,8522.21%+20%85,1906.9
Sep 30, 2026490,2911.84%-3%136,3313.6
Sep 15, 2026504,8621.89%-4%133,3353.8
Aug 31, 2026525,0251.97%+22%96,3925.5
Aug 14, 2026429,4471.61%-3%122,0563.5
Jul 31, 2026441,7681.74%-5%78,7405.6
Jul 15, 2026465,2321.83%+27%252,4281.8
Jun 30, 2026366,6951.44%-6%174,5452.1
Jun 15, 2026391,2131.54%+51%110,3653.5
May 29, 2026258,8981.02%-5%144,5391.8
May 15, 2026272,6791.07%+6%78,4183.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

ABVC Biopharma company events

ABVC Biopharma filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (restatement, auditor). The latest was on Nov 2, 2026.

  1. Nov 2, 2026AgreementABVC BioPharma, Inc. entered into a securities purchase agreement with certain accredited investors for the sale of original issue discount senior convertible promissory notes in an of $4.11 million for an aggregate purchase price of $3.39 million. Filing
  2. Aug 27, 2026DealThe information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. Filing
  3. Aug 12, 2026AnnouncementAmended an earlier report. ABVC BioPharma, Inc. determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc., which had been scheduled to occur on August 3, 2026. Filing
  4. Aug 4, 2026AnnouncementABVC BioPharma, Inc. determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc., which had been scheduled to occur on August 3, 2026. Filing
  5. Jul 2, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  6. Mar 27, 2026VoteReported shareholder vote results. Filing
  7. Mar 3, 2026RestatementThe Board of Directors of ABVC Biopharma, Inc., after discussion with management and in consultation with the Company’s independent registered public accounting firm, concluded that the financial statements for the quarterly period ended September 30, 2025, as included in the Company’s Quarterly… Filing
  8. Jan 16, 2026SharesAmended an earlier report. Sold new shares outside a public offering. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ABVC Biopharma financials

Famous investors that hold ABVC

1 of the 50 well-known investors we track reported holding ABVC in their latest 13F filing. The largest position is Ken Griffin's, worth $31.2K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202629,426$31.2K0.0%-59%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Abvc Biopharma, Inc. (ABVC) stock

Are ABVC insiders buying or selling?

No ABVC insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ABVC?

As of Oct 30, 2026, 602,938 ABVC shares were sold short, 2.3% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 30,302 shares, buying them all back would take about 19.9 trading days (days to cover). See the history.

Which famous investors hold ABVC?

1 of the 50 well-known investors we track reported ABVC in their latest 13F filing, including Ken Griffin. The largest position is worth $31.2K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.